INNOVATIVE EYEWEAR, INC. Research and Development Expense
INNOVATIVE EYEWEAR, INC. (LUCY) reported Research and Development Expense of $142.09 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- INNOVATIVE EYEWEAR, INC. research and development expense for the quarter ending 2026-06-30 was $142.09K, a 47.02% decline year-over-year.
- INNOVATIVE EYEWEAR, INC. research and development expense for the quarter ending 2026-03-31 was $138.11K, a 34.41% decline year-over-year.
- INNOVATIVE EYEWEAR, INC. research and development expense for the quarter ending 2025-12-31 was $116.60K, a 45.74% decline year-over-year.
- INNOVATIVE EYEWEAR, INC. research and development expense for the quarter ending 2025-09-30 was $129.98K, a 1.05% decline year-over-year.
- INNOVATIVE EYEWEAR, INC. research and development expense for fiscal 2025 was $725.39K, a 11.47% decline from fiscal 2024.
- INNOVATIVE EYEWEAR, INC. research and development expense for fiscal 2024 was $819.39K, a 23.74% increase from fiscal 2023.
- INNOVATIVE EYEWEAR, INC. research and development expense for fiscal 2023 was $662.18K, a 26.20% increase from fiscal 2022.
- INNOVATIVE EYEWEAR, INC. research and development expense for fiscal 2022 was $524.69K, a 508.26% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $142.09K 10-Q · filed 2026-08-14 | $280.20K 10-Q · filed 2026-08-14 | $396.81K derived: sum of 3 quarters · filed 2026-08-14 | $526.79K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $138.11K 10-Q · filed 2026-05-14 | $254.71K derived: sum of 2 quarters · filed 2026-05-14 | $384.70K derived: sum of 3 quarters · filed 2026-05-14 | $652.92K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $116.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $246.59K derived: sum of 2 quarters · filed 2026-03-25 | $514.81K derived: sum of 3 quarters · filed 2026-08-14 | $725.39K 10-K · filed 2026-03-25 |
| 2025-09-30 | $129.98K 10-Q · filed 2025-11-13 | $398.21K derived: sum of 2 quarters · filed 2026-08-14 | $608.78K 10-Q · filed 2025-11-13 | $823.70K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $268.22K 10-Q · filed 2026-08-14 | $478.80K 10-Q · filed 2026-08-14 | $693.72K derived: sum of 3 quarters · filed 2026-08-14 | $825.08K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $210.58K 10-Q · filed 2026-05-14 | $425.49K derived: sum of 2 quarters · filed 2026-05-14 | $556.86K derived: sum of 3 quarters · filed 2026-05-14 | $813.66K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $214.91K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $346.28K derived: sum of 2 quarters · filed 2026-03-25 | $603.09K derived: sum of 3 quarters · filed 2026-03-25 | $819.39K 10-K · filed 2026-03-25 |
| 2024-09-30 | $131.37K 10-Q · filed 2025-11-13 | $388.17K derived: sum of 2 quarters · filed 2025-11-13 | $604.47K 10-Q · filed 2025-11-13 | $725.31K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $256.80K 10-Q · filed 2025-08-14 | $473.10K 10-Q · filed 2025-08-14 | $593.94K derived: sum of 3 quarters · filed 2025-08-14 | $786.64K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $216.30K 10-Q · filed 2025-05-13 | $337.14K derived: sum of 2 quarters · filed 2025-05-13 | $529.84K derived: sum of 3 quarters · filed 2025-05-13 | $727.32K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $120.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $313.54K derived: sum of 2 quarters · filed 2025-03-24 | $511.01K derived: sum of 3 quarters · filed 2025-03-24 | $662.18K 10-K · filed 2025-03-24 |
| 2023-09-30 | $192.70K 10-Q · filed 2024-11-12 | $390.18K derived: sum of 2 quarters · filed 2024-11-12 | $541.35K 10-Q · filed 2024-11-12 | $672.98K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $197.48K 10-Q · filed 2024-08-12 | $348.65K 10-Q · filed 2024-08-12 | $480.28K derived: sum of 3 quarters · filed 2024-08-12 | $784.97K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $151.17K 10-Q · filed 2024-05-14 | $282.80K derived: sum of 2 quarters · filed 2024-05-14 | $587.49K derived: sum of 3 quarters · filed 2024-05-14 | $640.05K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $131.63K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $436.32K derived: sum of 2 quarters · filed 2024-03-25 | $488.88K derived: sum of 3 quarters · filed 2024-03-25 | $524.69K 10-K · filed 2024-03-25 |
| 2022-09-30 | $304.69K 10-Q · filed 2023-11-14 | $357.25K derived: sum of 2 quarters · filed 2023-11-14 | $393.06K 10-Q · filed 2023-11-14 | $443.20K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $52.56K 10-Q · filed 2023-08-11 | $88.37K 10-Q · filed 2023-08-11 | $138.51K derived: sum of 3 quarters · filed 2023-08-11 | $147.73K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $35.81K 10-Q · filed 2023-05-12 | $85.95K derived: sum of 2 quarters · filed 2023-05-12 | $95.17K derived: sum of 3 quarters · filed 2023-05-12 | $114.30K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $50.14K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $59.36K derived: sum of 2 quarters · filed 2023-03-24 | $78.49K derived: sum of 3 quarters · filed 2023-03-24 | $86.26K 10-K · filed 2023-03-24 |
| 2021-09-30 | $9.22K 10-Q · filed 2022-11-10 | $28.35K derived: sum of 2 quarters · filed 2022-11-10 | $36.12K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $19.13K 10-Q · filed 2022-09-26 | $26.90K 10-Q · filed 2022-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RxSight, Inc. (RXST) | United States | $0.197B | |
| STAAR SURGICAL CO (STAA) | United States | $0.957B | 362.70 |
| National Vision Holdings, Inc. (EYE) | United States | $1.297B | |
| Warby Parker Inc. (WRBY) | United States | $2.970B | |
| Bausch & Lomb Corp (BLCO) | Canada | $6.008B | -34.58 |
| COOPER COMPANIES, INC. (COO) | United States | $10.533B | 24.09 |